5/20/2018 Terlispressin Brand Communications Final

1/12

THINWES: BRAND INSIGHTS

A monthly update to keep you Info

TOPIC OF THE MONTH

5/20/2018 Terlispressin Brand Communications Final

2/12

BLEEDING OESOPHAGEAL VARICES: A MEDICAL BRIEF SNA

Portal hypertension isa major complicationof chronic liver disease.In cirrhosis,architectural distortion

of the liver causes anincrease in theintrahepatic vascular

resistance.

Gastro-oesophagealvarices form as a resultof increased portalpressure, the productof increased portal

venous inflow andresistance to outflowfrom the portal venoussystem

Gastro-oesophagealvarices are present inalmost half of patientsat the time of thediagnosis of cirrhosis

The 6-for varapproxand

recurrevaricea60%

1 2 3

5/20/2018 Terlispressin Brand Communications Final

3/12

5/20/2018 Terlispressin Brand Communications Final

4/12

BOV HRS : A Major complications of Cirrhosis

5/20/2018 Terlispressin Brand Communications Final

5/12

CURRENT RECOMMENDED MANAGEMENT OF PATIENTS WITH ACUTE VAR

BLEEDING

5/20/2018 Terlispressin Brand Communications Final

6/12

ROLE OF THINWES

Indications

Indications

In the management of :

Bleeding Oesophageal Varices

Hepato Renal Syndrome

Pharmacological

Benefits

significantly decreases portal venous flow

Decrease hepatic venous pressure gradient & mortality

Terlipressin & Albumin significantly decreases serum creatinine levels & improvefunction.

Dosage

Bleeding Oesophageal Varices is 2mg IV bolus every 4-6hrs which can be continumaximum of 72 hrs.

In Hepato renal Syndrome, the dosage is 1-2mg bolus every 4-6 hrs maximun of 6 hrs.

5/20/2018 Terlispressin Brand Communications Final

7/12

MECHANISM OF ACTION

5/20/2018 Terlispressin Brand Communications Final

8/12

THINWES ADVANTAGES

Highly efficacious in BOV with better survival rates which makes Terlipressinchoice amongst clinicians

Well documented benefits in Hepato Renal Syndrome

Single shot bolus every 4-6 hours

No Tachyphylaxis or desensitization with repeated dose

Lesser hospital stay

5/20/2018 Terlispressin Brand Communications Final

9/12

MARKET TREND

Brand Company Sum of MAT (May 13) Sum o

TERLYZ SUN* 7.7

TERLIFORCE ALEMBIC 3.4

THINWES BIOCON 0.8

TERLISTAT SAMARTH PHARMA 2

T-PRESSIN UNITED BIOTECH 0

REMESTYP FERRING PHARMA 0.7

TERLIBAX RANBAXY* 0

TRIPEZ UNIQUE PHARM 0.2

TRESIL SERUM INSTITUTE 0

TOTAL14.7

Total competitors: 9 Total Market Value: 18.2 Gr

5/20/2018 Terlispressin Brand Communications Final

10/12

COMPETITOR MARKET OVERVIEW

TERLYZ

49%

TERLIFORCE

17%

THINWES

16%

TERLISTAT

10%

T-PRESSIN

5%

REMESTYP

2%

TERLIBAX

1%

OTHER

0%

Brand Company Growth Volume led growth

(VLG)

Price led g

(PLG

TERLYZ SUN* 15% 12% 3%

TERLIFORCE ALEMBIC -10% -11% 1%

THINWES BIOCON 255% 255% 0%

TERLISTAT SAMARTH PHARMA -8% 14% -22%

T-PRESSIN UNITED BIOTECH - - -

REMESTYP FERRING PHARMA -32% -32% 0%

TERLIBAX RANBAXY* - - -

5/20/2018 Terlispressin Brand Communications Final

11/12

COMPETITOR PRICE INSIGHTS

Brand MRP

Thinwes (1 mg/10 ml) 2000/-Terlyz (1 mg/10 ml) 1380/-

Remestyp 2000/-

BRAND SEGMENTATION AND P

Strength Packing MRP (per vial)

Terlipressin inj.

1 mg

1mg / 10 ml

vial

2000

THINWES PACKAGING AND PRICING

Speciality Targeting

Targeted Drs/

TBM

Indicat

Gastroenterol

ogists (Surg. &

Physicians)

All BOV

Hepatologists All BOV

Intensivists All BOV, HRS

Con.

Physicians

20 BOV, HRS

BRAND INSIGHTS

5/20/2018 Terlispressin Brand Communications Final

12/12